) and H. Lundbeck A/S recently presented positive data on Azilect
from a double-blind, placebo controlled, randomized, multicenter
Teva and H. Lundbeck said that Azilect met its primary
endpoint in the ANDANTE (Add oN to Dopamine AgoNists in the
TrEatment of Parkinson's disease) study, which was conducted to
evaluate the efficacy and tolerability of Azilect as add-on
treatment to dopamine agonists compared to placebo.
Results showed that Azilect, when added to dopamine agonists,
achieved a statistically significant improvement in total Unified
Parkinson's Disease Rating Scale. Teva said that Azilect was
well-tolerated with no significant difference in adverse events
compared to placebo.
Azilect is currently approved for the treatment of the signs
and symptoms of Parkinson's disease both as initial monotherapy
and as an add-on treatment to levodopa later in the disease. This
is the first time that Azilect's efficacy in combination with
dopamine agonist monotherapy has been studied. The ANDANTE study
results provide the company with proof-of-concept for adding
Azilect to dopamine agonists.
We note that Azilect is currently in a phase IV study,
MODERATO (Multicenter, Randomized, Double-Blind,
Placebo-Controlled Study to Assess the Effect of Rasagiline on
Cognition in Patients with Parkinson's disease), which is being
conducted to evaluate the effect of Azilect on cognitive function
in adults with mild cognitive impairment (MCI) in Parkinson's
Azilect, which is a part of Teva's central nervous system
(CNS) portfolio, posted sales of $420 million in 2012, up 7%.
Other players in the Parkinson's disease market include
Teva currently carries a Zacks Rank #3 (Hold). Teva is going
through a transition period. Headwinds include EU pricing
pressure, potential new competition for branded products
(especially Copaxone) and fewer generic product launches compared
to 2012. We expect investor focus to remain on the execution of
the company's new strategy.
Currently, companies like
) look better-positioned. Both are Zacks Rank #2 (Buy) stocks.
UCB is a Zacks Rank #1 (Strong Buy) stock.
AKORN INC (AKRX): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.